

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Proposed Single Technology Appraisal (STA)

### Letermovir for preventing cytomegalovirus infection in sero-positive patients having allogeneic haematopoietic stem cell transplantation ID1153

#### Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> <li>Merck, Sharp &amp; Dohme (letermovir)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>African Caribbean Leukaemia Trust</li> <li>Anthony Nolan</li> <li>Bloodwise</li> <li>Cancer52</li> <li>Cancer Black Care</li> <li>Cancer Equality</li> <li>Chronic Lymphocytic Leukaemia Support Association</li> <li>Chronic Myeloid Leukaemia Support Group</li> <li>DKMS</li> <li>Equalities National Council</li> <li>HAWC</li> <li>Helen Rollason Cancer Charity</li> <li>Independent Cancer Patients Voice</li> <li>Leukaemia Cancer Society</li> <li>Leukaemia Care</li> <li>Lymphoma Association</li> <li>Macmillan Cancer Support</li> <li>Maggie's Centres</li> <li>Marie Curie</li> <li>Muslim Council of Britain</li> <li>Primary Immunodeficiency UK</li> <li>South Asian Health Foundation</li> <li>Specialised Healthcare Alliance</li> <li>Tenovus Cancer Care</li> <li>UK Primary Immunodeficiency Network</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>British Blood Transfusion Society</li> <li>British Committee for Standards in Haematology</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>All Wales Therapeutic and Toxicology Centre</li> <li>Allied Health Professionals Federation</li> <li>Board of Community Health Councils in Wales</li> <li>British National Formulary</li> <li>British Society of Blood and Marrow Transplantation</li> <li>Care Quality Commission</li> <li>Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>Healthcare Improvement Scotland</li> <li>Medicines and Healthcare Products Regulatory Agency</li> <li>National Association for Primary Care</li> <li>National Pharmacy Association</li> <li>NHS Alliance</li> <li>NHS Commercial Medicines Unit</li> <li>NHS Confederation</li> <li>Scottish Medicines Consortium</li> <li>United Kingdom National Screening Committee</li> <li>Welsh Health Specialised Services Committee</li> </ul> <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> <li>Actavis (aciclovir, valaciclovir)</li> <li>Accord Healthcare (valganciclovir)</li> <li>Aurobindo (valaciclovir, valganciclovir)</li> <li>Clinigen (foscarnet)</li> <li>GlaxoSmithKline (aciclovir, valaciclovir)</li> <li>Hospira (aciclovir)</li> <li>Roche Products (ganciclovir, valganciclovir)</li> <li>Rosemont (aciclovir)</li> <li>Sun pharmaceutical (acyclovir,</li> </ul>

National Institute for Health and Care Excellence

Provisional matrix for the proposed technology appraisal of letermovir for preventing cytomegalovirus infection in sero-positive patients having allogeneic haematopoietic stem cell transplantation ID1153

Issue date: July 2017

Page 1 of 3

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> <li>British Geriatrics Society</li> <li>British Institute of Radiology</li> <li>British Society for Haematology</li> <li>British society of Immunology</li> <li>British Transplantation Society</li> <li>NHS Blood and Transplant</li> <li>Royal College of General Practitioners</li> <li>Royal College of Nursing</li> <li>Royal College of Pathologists</li> <li>Royal College of Physicians</li> <li>Royal College of Radiologists</li> <li>Royal Pharmaceutical Society</li> <li>Royal Society of Medicine</li> <li>Society and College of Radiology</li> <li>UK Chronic Lymphocytic Leukaemia Forum</li> <li>UK Clinical Pharmacy Association</li> <li>UK Health Forum</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>Department of Health</li> <li>NHS England</li> <li>NHS Barnet CCG</li> <li>NHS East and North Hertfordshire CCG</li> <li>Welsh Government</li> </ul>	<ul style="list-style-type: none"> <li>valaciclovir)</li> <li>Thame Laboratories (aciclovir)</li> <li>Thea pharmaceuticals (ganciclovir)</li> <li>Thorton &amp; Ross (aciclovir)</li> <li>Wockhardt (aciclovir)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>Cochrane Haematological Malignancies Group</li> <li>European Group for Blood and Marrow Transplantation</li> <li>Leuka</li> <li>Leukaemia Busters</li> <li>Lymphoma Research Trust</li> <li>MRC Clinical Trials Unit</li> <li>National Institute for Health Research</li> </ul> <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> <li>Public Health England</li> <li>Public Health Wales</li> </ul>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

***PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS***

### Definitions:

#### Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-company consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

#### Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

---

<sup>1</sup> Non-company consultees are invited to submit statements relevant to the group they are representing.